ICAM1 and melanoma: We speculate that the differentiation status of wildtype NRAS/BRAF melanomas impacts on the prognostic utility of ICAM-1, as more than three quarters of the wildtype NRAS/BRAF tumors had high PMEL levels and thus were derived from well differentiated melanocytes.